Barbiturates Screen With Reflex Confirmation, Whole Blood
Use
This test is used to screen for the presence of barbiturates in a whole blood specimen. Initial presumptive testing is conducted using an immunoassay method at a screening threshold of 0.1 μg/mL. If the initial screen is positive, reflex confirmation is performed using chromatography mass spectrometry (GC/MS or LC/MS-MS) to provide a definitive analysis. Barbiturates are central nervous system depressants and are often a subject of drug abuse or overdose investigations.
Special Instructions
For the initial screening, an immunoassay is used, and presumptive positive results are confirmed with GC/MS or LC/MS-MS. Ensure proper specimen collection and handling to maintain integrity, including using appropriate tubes such as gray-top, green-top, or lavender-top.
Limitations
This test has been developed and performance characteristics determined by LabCorp, but it has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Results are intended for medical use and should be interpreted by qualified healthcare professionals. Temperature and storage conditions may affect specimen integrity, so follow proper storage instructions closely.
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 3376-1
- 82973-9
- 82972-1
- 82971-3
- 82969-7
- 82970-5
- 82968-9
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL
Minimum Volume
3 mL
Container
Gray-top (sodium fluoride/potassium oxalate) tube, green-top (heparin) tube, or lavender-top (EDTA) tube
Storage Instructions
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.
Other tests from different labs that may be relevant